Compare ABUS & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | EVC |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.0M | 683.9M |
| IPO Year | 2008 | 2000 |
| Metric | ABUS | EVC |
|---|---|---|
| Price | $4.35 | $6.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 1.1M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 55.26 | 47.59 |
| EPS | ★ 0.84 | 0.32 |
| Revenue | $14,083,000.00 | ★ $536,034,000.00 |
| Revenue This Year | $1,208.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $4.98 | $19.09 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.50 | $1.95 |
| 52 Week High | $5.45 | $13.74 |
| Indicator | ABUS | EVC |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 25.22 |
| Support Level | $4.17 | $2.90 |
| Resistance Level | $4.57 | $10.09 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 15.43 | 3.40 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.